Efficacy and safety of sugammadex in patients undergoing renal transplantation
Efficacy and safety of sugammadex in patients undergoing renal transplantation
复制标题
DOI：
10.1186/s40981-018-0192-z
复制
发表时间：
2018-07-25
影响因子：
0.9
通讯作者：
Fujiwara, Yoshihiro
中科院分区：
文献类型：
--
作者：
Ono, Yasumasa;Fujita, Yoshihito;Fujiwara, Yoshihiro
背景：Sugammadex通过包裹罗库溴铵，形成稳定的复合物，主要由肾脏排泄，从而逆转罗库溴铵。尽管如此，考虑到肾移植期间sugammadex的暴露，目前的安全性数据并不充分。我们回顾性研究了sugammadex在围手术期和长期随访中的安全性和有效性。病例介绍：我们研究了99例连续的活体肾移植患者。我们研究了sugammadex在外科重症监护室的前48-72 h和6个月随访中的疗效及其围手术期并发症。中位血清肌酐浓度为5.6 mg/dl，血尿素氮（BUN）为30 mg/dl。术中罗库和sugammadex的中位剂量分别为160 mg（四分位数范围130-185 mg）和200 mg（200-200 mg）。移植后，术后第1天的中位血清肌酐浓度为2.4 mg/dl，BUN为21 mg/dl。结论：我们调查了99例连续肾移植患者使用sugammadex是否会获益。未发生不良事件。我们得出结论，在我们的观察期内，sugammadex对肾移植患者有效且安全。
Background: Sugammadex reverses rocuronium by encapsulating it, creating a stable complex that is mainly excreted by the kidneys. Nonetheless, in view of exposure to sugammadex during renal transplantation, current safety data are insufficient. We retrospectively investigated the safety and efficacy of sugammadex in the immediate perioperative period and over long-term follow-up.Case presentation: We studied 99 consecutive patients who underwent living renal transplantation. We investigated the efficacy of sugammadex and its perioperative complications in the first 48-72 h in the surgical intensive care unit and in the follow-up for 6 months.Before transplantation, 53 patients required hemodialysis. The median serum creatinine concentration was 5.6 mg/dl, and blood urea nitrogen (BUN) was 30 mg/dl. During surgery, the median rocuronium and sugammadex dose was 160 mg (interquartile range 130-185 mg) and 200 mg (200-200 mg), respectively. After transplantation, the median serum creatinine concentration was 2.4 mg/dl at postoperative day 1, and BUN was 21 mg/dl, respectively. No adverse events were recorded during the observation period.Conclusion: We investigated whether 99 consecutive patients undergoing renal transplantation may benefit from the use of sugammadex. There were no adverse events. We concluded that, in our observational period, sugammadex was efficacious and safe in patients who underwent renal transplantation.